4basebio PLC
88Q
Company Profile
Business description
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Contact
25 Norman Way
Over
CambridgeCB24 5QE
GBRT: +44 1223967943
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
110
Stocks News & Analysis
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,351.90 | 4.90 | -0.05% |
| CAC 40 | 8,239.18 | 13.55 | 0.16% |
| DAX 40 | 24,308.78 | 68.89 | 0.28% |
| Dow JONES (US) | 47,433.52 | 226.40 | 0.48% |
| FTSE 100 | 9,653.82 | 8.20 | 0.09% |
| HKSE | 26,433.70 | 273.55 | 1.05% |
| NASDAQ | 23,605.29 | 400.42 | 1.73% |
| Nikkei 225 | 50,512.32 | 1,212.67 | 2.46% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,861.38 | 69.69 | 1.03% |
| S&P/ASX 200 | 9,055.60 | 2.20 | -0.02% |
| SSE Composite Index | 3,996.94 | 46.63 | 1.18% |